Ozempic Guide
Ozempic is the brand-name formulation of semaglutide FDA-approved for type 2 diabetes management, though it has become widely prescribed off-label for weight loss. It is available in doses of 0.5mg, 1mg, and 2mg weekly, and is manufactured by Novo Nordisk. Ozempic also carries an FDA indication to reduce cardiovascular risk in adults with type 2 diabetes and heart disease.
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
At a Glance
How Ozempic Works
Ozempic activates GLP-1 receptors to stimulate glucose-dependent insulin secretion, suppress glucagon, and reduce blood sugar levels. The same mechanism that controls blood glucose also suppresses appetite and slows gastric emptying, producing significant weight loss as a secondary effect. At 1–2mg doses, Ozempic delivers strong appetite suppression comparable to Wegovy's lower dose range.[2][3]
Dosing Schedule
Ozempic uses a gradual dose escalation to minimize side effects. Always follow your prescriber's guidance and the current FDA label[1].
Side Effects
Common: nausea, vomiting, diarrhea, stomach pain, constipation. Injection site reactions are common in early weeks. Serious (rare): pancreatitis, diabetic retinopathy worsening, kidney injury, hypoglycemia when combined with sulfonylureas or insulin. Thyroid C-cell tumor risk noted in animal studies.[1][2]
This is not a complete list. Consult your healthcare provider or prescriber for full safety information. The complete adverse reaction profile is published in the current FDA prescribing information[1].
Clinical Trial Results
In the SUSTAIN-6 cardiovascular trial, Ozempic reduced the risk of major cardiovascular events by 26% vs. placebo (Marso et al. NEJM 2016, PMID 27633186). For weight loss specifically, the STEP-8 head-to-head trial (Rubino et al. JAMA 2022, PMID 34962517) used semaglutide 2.4 mg — the Wegovy dose, not the Ozempic 1 mg dose — and showed 15.8% weight loss vs 6.4% for liraglutide 3 mg. Ozempic itself is FDA-approved only for type 2 diabetes; Wegovy is the FDA-approved semaglutide for chronic weight management.[2]
Where to Get Ozempic
These telehealth providers offer access to semaglutide or compounded equivalents with online consultations and home delivery.
Editorial score · methodology
Calibrate Health
Best for: patients with insurance coverage who want a year-long coaching-wrap around branded Wegovy / Zepbound / Foundayo
Editorial score · methodology
Gala
Best for: compounded GLP-1/GIP combo therapy on a yearly subscription with free shipping nationwide
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Cost Comparison
Starting prices for compounded GLP-1 medications from top providers, sorted cheapest first. Compounded semaglutide from licensed 503A and 503B pharmacies is legal under federal compounding law[4], with additional tolerances historically allowed while the molecule has appeared on the FDA Drug Shortage List[5]. Both compounded and brand-name prescriptions are generally FSA/HSA eligible under IRS Publication 502[6]. Prices may vary based on dose and promo availability.
| Provider | Starting Price | |
|---|---|---|
| AM Rx | $25/mo | Visit |
| Calibrate Health | $25/mo | Visit |
| FitRx | $25/mo | Visit |
| Roen Rx | $25/mo | Visit |
| Cost Plus Drugs | $279/mo | Visit |
| Synergy Rx | $499/mo | Visit |
| Care Bare Rx | $705/mo | Visit |
| Push Health | $950/mo | Visit |
| Vaylen | $997/mo | Visit |
| altRX | $1149/mo | Visit |
| Navio MD | $1199/mo | Visit |
| Healthicare | $1200/mo | Visit |
| Gala | $1299/mo | Visit |
| Effecty | $1300/mo | Visit |
| Ark Health | $1399/mo | Visit |
| Eve | $1399/mo | Visit |
| Concierge MD LA | $1999/mo | Visit |
Related Research on Ozempic
Deep-dive articles from our research desk with primary-source trial data, FDA label verification, and editorial analysis.
Frequently Asked Questions
Sources & methodology — as of May 2026
- 1.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 2.SUSTAIN-6 Trial — Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (Marso SP et al.)— New England Journal of Medicine.PMID: 27633186.
- 3.ADA — Standards of Care in Diabetes (2025)— American Diabetes Association.
- 4.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 5.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 6.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.
Glossary references
Key terms in this article, linked to their canonical definitions.
- Semaglutide · Drugs and brands
- Wegovy · Drugs and brands
- Rybelsus · Drugs and brands
- GLP-1 receptor · Mechanism
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
- Ozempic face · Side effects